Shares of Novavax Inc. NVAX, +4.93% were down 6.7% in premarket trading on Tuesday, the day after the company fell short of revenue expectations for the fourth quarter of 2021. Novavax on Monday reported $222.2 million in revenue in the fourth quarter of 2021. The FactSet consensus was $331.8 million. The company’s protein-based COVID-19 vaccine is its only authorized or approved therapy; it recently received authorization in several regions, including the European Union, New Zealand, and the U.K. (The shot is currently under review in the U.S.) Novavax’s stock has tumbled 65.3% over the past year, while the broader S&P 500 SPX, -0.66% is up 14.4%.
View Article Origin Here
